Whitehawk Therapeutics Details ADC Pipeline Progress and 2028 Cash Runway
Whitehawk Therapeutics CEO detailed progress on its lead antibody–drug conjugate programs, highlighting entry of a solid tumor candidate into phase II studies. He confirmed the company maintains a cash runway through 2028, underpinning ongoing development of next-generation targeted therapies.
1. Conference Presentation
At the recent Aadi Bioscience conference, Whitehawk Therapeutics’ CEO provided an in-depth update on the company’s strategic focus, emphasizing both scientific progress and financial stability. He underscored the importance of advancing targeted therapies to address unmet needs in oncology.
2. ADC Pipeline Development
The CEO spotlighted multiple antibody–drug conjugate programs, noting that the lead solid tumor candidate has successfully initiated phase II studies. He outlined plans to expand preclinical work on next-generation ADCs aimed at hematologic and solid malignancies.
3. Financial Outlook
Management affirmed that existing capital resources will fund operations through 2028, ensuring uninterrupted support for ongoing clinical trials and preclinical research. This runway is expected to position the company to reach key value-creating milestones without near-term financing.